Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib
Authors
Keywords
-
Journal
DRUG METABOLISM REVIEWS
Volume 47, Issue 1, Pages 21-28
Publisher
Informa UK Limited
Online
2015-02-02
DOI
10.3109/03602532.2014.1003648
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A highly selective probe for human cytochrome P450 3A4: isoform selectivity, kinetic characterization and its applications
- (2013) Guang-Bo Ge et al. CHEMICAL COMMUNICATIONS
- Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTTO Trial
- (2013) Hatem A. Azim et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence
- (2012) Yi Ling Teo et al. BREAST CANCER RESEARCH AND TREATMENT
- The Adjuvant Treatment of HER2-Positive Breast Cancer
- (2012) Danijela Jelovac et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors
- (2012) Maja J. A. de Jonge et al. INVESTIGATIONAL NEW DRUGS
- Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates
- (2011) AM Filppula et al. BRITISH JOURNAL OF PHARMACOLOGY
- Pharmacokinetic evaluation of the vinorelbine–lapatinib combination in the treatment of breast cancer patients
- (2011) Keyvan Rezai et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Metabolic Intermediate Complex Formation of Human Cytochrome P450 3A4 by Lapatinib
- (2011) H. Takakusa et al. DRUG METABOLISM AND DISPOSITION
- HLA-DQA1*02:01 Is a Major Risk Factor for Lapatinib-Induced Hepatotoxicity in Women With Advanced Breast Cancer
- (2011) Colin F. Spraggs et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanism-Based Inactivation of Cytochrome P450 3A4 by Lapatinib
- (2010) W. C. Teng et al. MOLECULAR PHARMACOLOGY
- Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects
- (2009) Deborah A. Smith et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Lapatinib
- (2009) James E. Frampton DRUGS
- Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction
- (2008) Roger K. Verbeeck EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer
- (2008) Henry L. Gomez et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started